Safety of and Immune Response to Dolutegravir (GSK1349572) in HIV-1 Infected Infants, Children, and Adolescents

This study is currently recruiting participants. (see Contacts and Locations)

Verified February 2015 by National Institute of Allergy and Infectious Diseases (NIAID)

Sponsor:

Information provided by (Responsible Party):

National Institute of Allergy and Infectious Diseases (NIAID)

ClinicalTrials.gov Identifier:

NCT01302847

First received: February 15, 2011

Last updated: February 20, 2015

Last verified: February 2015

No Study Results Posted on ClinicalTrials.gov for this Study

Study Status:	This study is currently recruiting participants.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	May 2018 (Final data collection date for primary outcome measure)